Introduction
Chronic myeloid leukemia (CML) is a clonal malignancy of the hematopoietic stem cell characterized by massive overproduction of granulocytic cells. 1 CML cells harbor a 9;22 translocation, which fuses the abl proto-oncogene to the bcr gene. The fusion gene encodes a novel 210 kDa protein with constitutive tyrosine kinase activity that is necessary and sufficient for cell transformation. The principal pharmacological therapy for CML is interferon-␣ (IFN-␣), which is capable of inducing major cytogenetic remissions in 10-20% of CML patients. [1] [2] [3] The discovery of IFN-␣ as an effective CML treatment was serendipitous and its mechanism of action is unknown.
Dendritic cells (DCs) are potent antigen-presenting cells derived from hematopoietic progenitors. 4, 5 Immature DCs uptake and process antigen in the peripheral tissues, then migrate to lymphoid organs where they mature and present processed antigen to T lymphocytes. The transition of DCs from antigen-processing cells to mature antigen-presenting cells is accompanied by upregulation of class I and class II major histocompatibility complex proteins, and B7 co-stimulatory molecules (CD80, CD86) and various adhesion molecules that enhance their ability to present antigen and activate T lymphocytes. 6 DCs occur rarely in the blood but they can be derived from peripheral blood monocytes by culturing them in interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF). [7] [8] [9] This culture method, and others, have been used to prepare DCs from peripheral blood or bone marrow cells of CML patients. [10] [11] [12] [13] [14] [15] The DCs have been shown to be derived from the leukemic clone and therefore, they should be capable of presenting CML-specific antigens to cytotoxic T lymphocytes. As a result, preliminary clinical trials using ex vivo generated CML DCs as immunotherapy for CML have been conducted. [16] [17] [18] We previously reported that peripheral blood monocytes cultured in media containing IFN-␣ and GM-CSF differentiated into DCs. 19 Because IFN-␣ is used as immunotherapy for various malignancies, including CML, it is possible that the therapeutic efficacy of this agent may be partially due to its affect on DC development. Therefore, the ability of IFN-␣ to differentiate CML mononuclear cells into DCs was evaluated.
Materials and Methods

Culture methods
Peripheral blood mononuclear cells were obtained from heparinized blood of CML patients and normal human donors by Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation. The mononuclear cell fraction was washed three times with phosphate-buffered saline (PBS), resuspended in RPMI 1640 media (Gibco BRL, Gaithersburg, MD, USA) at 0.5-1.0 × 10 7 cells/ml, and seeded into 25 cm 2 flasks (Costar, Cambridge, MA, USA) at 8 ml/flask. The flasks were incubated at 37°C for 2 h, then the nonadherent cells were decanted. The adherent cell population was rinsed gently with RPMI 1640. 'Complete medium' containing penicillin-streptomycin (100 IU/ml and 100 g/ml, respectively; Mediatech, Herndon, VA, USA) and 10% AB serum (Gibco BRL) was added to the adherent cells. Optimal concentrations of cytokines determined by titration experiments were used except as indicated: IFN-␣-2b 2000 U/ml (Schering, Kenilworth, NJ, USA), GM-CSF 500 U/ml (10 4 U/mg; Pepro Tech, Rocky Hill, NJ, USA), and IL-4 1000 U/ml (2.9 × 10 4 U/mg; R&D Systems, Minneapolis, MN, USA). 18 The DCs were cultured for 7 days without the addition of supplemental media or cytokines. To induce maturation, DCs were incubated with mouse fibroblasts stably expressing human CD40 ligand for 12 h (gift of Gordon Freeman, Dana-Farber Cancer Institute, Boston, MA, USA).
Immunofluorescent staining and flow cytometry
Cells were incubated with saturating concentrations of fluorochrome-conjugated monoclonal antibodies at 4°C for 20 min, then were washed twice with cold PBS. Data were collected using a FACScanII flow cytometer and Lysys II acquisition software (Becton Dickinson, San Jose, CA, USA); data analyses were performed using CellQuest software (Becton Dickinson). Calibration for three-color flow cytometry was conducted using CaliBRITE beads and AutoCOMP software (Becton Dickinson). The following fluorochrome-conjugated mouse monoclonal antibodies against human proteins were used for immunofluorescent staining: fluorescein isothiocyanate (FITC)-conjugated anti-CD40, FITC-conjugated anti-CD83 and PE-conjugated anti-CD86 (all from PharMingen, San Diego, CA, USA); FITC-conjugated anti-CD14, PE-conjugated anti-CD54 and PE-conjugated anti-HLA-A, B, C (all from Caltag, San Francisco, CA, USA); PE-conjugated anti-CD80 and PerCP-conjugated anti-HLA-DR (both from Becton Dickinson).
Fluorescence in situ hybridization (FISH)
Cytospin preparations were made of CML DCs grown in IFN-␣/GM-CSF. The slides were air-dried and dehydrated in a graded ethanol series (70%, 80%, 100%) for 3 min each. DNA in the cells was denatured in 70% formamide in 2 × SSC (pH 7.0; 73°C) for 3 min, followed by dehydration in a graded ethanol series (70%, 80%, 100%) at 4°C. The slides were then dried on a platform heater for 5 min at 47°C. The LSI bcr/abl dual-color probe (Vysis, Downers Grove, IL, USA) was denatured, applied to slides and incubated at 37°C for 24 h according to the manufacturer's specifications to detect the presence of the bcr/abl chimeric fusion oncogene.
Mixed leukocyte reaction
T lymphocytes present in the nonadherent fraction of mononuclear cells isolated by Ficoll-Paque density gradient centrifugation were purified by passage over a T cell enrichment column (R&D Systems) according to the manufacturer's instructions. Purified T lymphocytes were counted and seeded into plates (96 round-bottomed wells/plate; Costar) at 10 5 cells/well. Purified allogeneic DCs were added to the T cells at varying ratios in triplicate wells. The final volume of each well was adjusted to 200 ml of complete medium. After 4 days of culture, 1 mCi of methyl-3 H thymidine (1 mCi/ml; DuPont NEN, Boston, MA, USA) was added to each well and incubation was continued for an additional 18 h. Cells were collected on fiber disks using a PhD Cell Harvester (Cambridge Technology, Cambridge, MA, USA) and thymidine uptake was quantitated by liquid scintillation counting.
Immunohistochemistry
Paraffin-embedded bone marrow biopsy sections were deparaffinized, incubated with mouse monoclonal antibody against human fascin, 20 CD1a or CD68, and subjected to a five-step alkaline phosphatase anti-alkaline phosphatase technique, as previously described. 21 
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Quantitation of bone marrow DCs
Bone marrow biopsy samples stained with anti-fascin antibodies were examined at ×400. Cells with a DC morphology were quantitated and cellularity was assessed for 10 fields. The mean DC density per slide was divided by the mean cellularity to obtain an adjusted DC density.
Statistical analysis
The mean levels of each DC surface marker were compared between treatment groups by using the Student's t-test. The same method was used to compare the adjusted DC densities in the bone marrow biopsy samples before and during IFN-␣ therapy.
Results
The effect of IFN-␣ on DC differentiation
Peripheral blood mononuclear cells from CML patients grown with IFN-␣/GM-CSF displayed eccentric and bi-lobed nuclei, and numerous fine cytoplasmic projections consistent with an immature DC morphology (Figure 1 ). These DCs were shown to be derived from the CML clone by FISH, which demonstrated the presence of the bcr/abl fusion in all of the evaluable DCs (Figure 2 ).
The immunophenotype of CML DCs
The effect of IFN-␣/GM-CSF, IL-4/GM-CSF or all three cytokines on the immunophenotypes of DCs prepared from PBMCs of six newly diagnosed CML patients was evaluated. The DCs grown in IFN-␣/GM-CSF expressed significantly higher levels of class I and II HLA proteins than those prepared with IL-4/GM-CSF (Figure 3) . The DCs cultured with all three cytokines expressed significantly higher levels of CD86 than DCs grown in IFN-␣/GM-CSF.
Figure 1
Morphology of CML DCs. The DCs were prepared by culturing CML PBMCs in media containing IFN-␣, GM-CSF and 10% AB serum for 7 days. Cytospin preparations were stained with Wright's Giemsa and examined at ×400.
Figure 2
CML DCs harbor the bcr/abl translocation. Cytospin samples of CML DCs grown in media containing IFN-␣/GM-CSF were subjected to FISH using a bcr/abl dual-color probe. A yellow bcr/abl fusion signal, indicated by the arrow, was observed in all of the evaluable DCs.
Figure 3
Immunophenotypes of CML DCs prepared using various cytokine combinations. The effect of IFN-␣/GM-CSF, IL-4/GM-CSF or all three cytokines on the immunophenotypes of DCs prepared using PBMCs from six newly diagnosed CML patients was evaluated. The results represent the mean and standard deviation of data from six individuals in each group. The two-tailed Student's t-test was used to evaluate differences in the mean levels of protein expression between treatment groups.
Immunophenotypes of CML and normal DCs
The DCs from normal individuals and newly diagnosed CML patients prepared with IFN-␣/GM-CSF, did not express significantly different levels of DC proteins (Figure 4) . However, DCs from CML patients who failed to experience a cytogenetic response after at least 6 months of IFN-␣ treatment had significantly lower expression of the CD80 and CD86 costimulatory molecules, CD40, class I HLA and the CD54 adhesion molecule than DCs from normal donors (Figure 4) . They also expressed significantly less CD40 and HLA-DR than DCs grown from CML patients prior to IFN-␣ treatment. Preparation of DCs from IFN-␣ unresponsive patients using IFN-
Figure 4
DCs from IFN-␣ refractory CML patients have an abnormal immunophenotype. The PBMCs from normal donors, newly diagnosed CML patients and CML patients who failed to respond to IFN-␣ were cultured in media containing IFN-␣, GM-CSF and 10% AB serum for 7 days then subjected to flow cytometry. The results represent the mean and standard deviation of data from five individuals in each group. The two-tailed Student's t-test was used to evaluate differences in the mean levels of protein expression between the groups.
Figure 5
Partial restoration of normal immunophenotype on DCs from IFN-␣ refractory CML patients. The PBMCs from normal donors and CML patients who failed to respond to IFN-␣ were cultured in complete media containing IFN-␣/GM-CSF, IL-4/GM-CSF or all three cytokines for 7 days then were subjected to flow cytometry. The results represent the mean and standard deviation of data from four individuals in each group. ␣/IL-4/GM-CSF resulted in higher CD86 and HLA-DR expression than when the DCs were grown in either two cytokine combination ( Figure 5) . A very similar effect was observed in the newly diagnosed CML patients (Figure 3) .
The frequency of DCs in cultures from IFN-␣ refractory CML PBMCs was similar to that of DCs from normal PBMC cultures for each combination of cytokines. The CML DCs comprised 55 ± 34%, 44 ± 26%, and 43 ± 36% of the cells harvested from cultures containing IFN-␣/GM-CSF, IL-4/GM-CSF and IFN-␣/IL-4/GM-CSF, respectively, while normal DCs were present at frequencies of 44 ± 23%, 39 ± 24% and 34 ± 22%, respectively. In contrast, DCs cultured from newly diagnosed CML patients comprised 20 ± 14%, 28 ± 21% and 27 ± 19% of the cells harvested from cultures containing IFN-␣/GM-CSF, IL-4/GM-CSF and IFN-␣/IL-4/GM-CSF, respectively. These percentages were lower than those from cultures of PBMCs from normal donors or treated CML patients because higher numbers of contaminating myeloid cells were present in cul-
Figure 6
Effect of CD40 ligation on CML DCs. The PBMCs from four normal donors and four CML patients who failed to respond to IFN-␣ were cultured in complete media containing IFN-␣ (1000 U/ml) and GM-CSF for 7 days, then incubated with fibroblasts expressing CD40 ligand, or in media and cytokines alone, for 12 h. The DCs were assessed for (a) CD83 and (b) CD86 expression by flow cytometry.
tures initiated with PBMCs from CML patients with elevated white blood counts.
Maturation of CML DCs
The DCs from IFN-␣ refractory CML patients were capable of maturing when exposed to fibroblasts expressing CD40 ligand, as evidenced by an increase in the proportion of cells expressing CD83 (Figure 6a) . A concomitant modest increase in CD86 levels was observed, but the level of expression remained inferior to that of normal DCs (Figure 6b ).
Allostimulatory activity of CML DCs
The allostimulatory activity of DCs from CML patients who had not achieved a cytogenetic response to IFN-␣, and that of DCs from normal donors, was compared using the mixed
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Figure 7
Allostimulatory activity of CML and normal DCs. DCs from CML patients who failed to respond to IFN-␣, and normal DCs, prepared using IFN-␣/GM-CSF were evaluated using the allogeneic MLR assay. The DCs were radiated, purified by negative depletion, and added in varying numbers (200, 1000 or 5000) to triplicate wells containing 10 5 allogeneic T lymphocytes in complete medium. After 4 days of co-culture, leukocyte reaction (Figure 7 ). Normal DCs were consistently better stimulators of allogeneic T cells than DCs from the CML patients at all DC:T cell ratios in four experiments, but the differences only approached statistical significance (P = 0.08, 0.06 and 0.16 for DC:T cell ratios of 1:500, 1:100 and 1:20, respectively).
Evaluation of DCs in CML bone marrows
DCs were visualized in bone marrow biopsies from CML patients, or patients with hematologic malignancies in remission, by performing immunohistochemistry with an antibody to fascin. Cells positive for fascin expression included vascular endothelial cells and cells with a dendritic morphology. The DCs did not express the macrophage marker CD68, the Langerhan's cell marker CD1a or CD34. The DCs in bone marrows of CML patients receiving IFN-␣ were larger than those those present prior to treatment, or those observed in control marrows (Figure 8 ).
CML patients who had at least a partial cytogenetic response (у 20% normal metaphases) to IFN-␣ initially had low numbers of bone marrow DCs (3.6 ± 2.4/HPF), comparable to those present in the control bone marrows (2.8 ± 1.3/HPF; P = 0.6). The bone marrow DC numbers increased significantly with treatment in the IFN-␣-responsive patients (14 ± 4/HPF, P = 0.01; Figures 8 and 9 ). In contrast, IFN-␣ nonresponders had more prevalent DCs at baseline (20 ± 16/HPF), and no consistent change in DC numbers occurred with treatment (18 ± 18/HPF, P = 0.9; Figure 9 ).
Discussion
This study demonstrates that PBMCs from CML patients, when cultured in IFN-␣/GM-CSF, differentiated into DCs. The cellular morphology and absent expression of CD83 suggests that they are immature DCs. Normal PBMCs cultured under these conditions have a similar morphology and immunopheno- type. 19 The CML DCs cultured in either IFN-␣/GM-CSF or IL-4/GM-CSF expressed similar levels of DC antigens, except the class I and II HLA proteins which were significantly more abundant on DCs grown in IFN-␣/GM-CSF. Normal DCs prepared with IFN-␣/GM-CSF also express higher levels of HLA proteins than those grown in IL-4/GM-CSF. 19 This effect is at least partly related to the ability of IFN-␣ to activate class I HLA gene transcription. The CML DCs cultured in IFN-␣/IL-4/GM-CSF expressed levels of CD86 that were higher than those present on DCs prepared with either two cytokine combination; this was also observed in experiments with normal DCs. 19 Therefore, CML PBMCs can be induced to differentiate into cells with the morphologic and immunophenotypic characteristics of DCs.
The immunophenotypes of DCs prepared from the PBMCs of newly diagnosed CML patients and normal donors were not significantly different. In contrast, CML patients who failed to experience a cytogenetic response to IFN-␣, or who relapsed after achieving an initial cytogenetic response, generated DCs in vitro that were deficient in class I HLA, CD80 and CD86 costimulatory molecules, CD40 and the CD54 adhesion protein.
Although the DCs from IFN-␣ refractory CML patients were induced to mature when exposed to CD40 ligand, as evi-
Figure 9
Effect of IFN-␣ treatment on DC density in the bone marrows of CML patients. Paraffin-embedded bone marrow biopsy specimens from CML patients at diagnosis and at first available follow-up after starting IFN-␣ were subjected to immunohistochemical analysis of fascin expression. Controls were morphologically normal bone marrow biopsies from patients with hematologic malignancies in remission after chemotherapy. The fascin-positive DCs were quantitated at ×400 and their density was adjusted for the cellularity of the field. The IFN-␣ responders were patients who achieved at least a partial reduction (у20%) in Ph + metaphases while the IFN-␣ failures showed no cytogenetic response.
denced by an increased percentage of cells positive for CD83, there was only minor improvement in CD86 expression. This suggests that CD40 signaling remains intact in the CML DCs, in spite of decreased CD40 expression, but regulation of costimulatory molecule expression is defective. The DCs cultured from IFN-␣ resistant patients also had lower MLR activity than DCs from normal individuals. These results suggest that defective DC maturation and function may play a role in the development of clinical resistance to IFN-␣.
The CML DCs generated in vivo by IFN-␣ treatment should be capable of presenting CML-specific antigens, thereby stimulating a cytotoxic T lymphocyte response against the CML clone. Therefore, there would be substantial selection pressure for the CML clone to evolve resistance to IFN-␣-induced DC differentiation. If the DC differentiating effects of IFN-␣ underlie its clinical efficacy in CML, then impairment of this process is a plausible mechanism for the development of drug resistance by the clone.
Expression of the co-stimulatory B7 molecules, CD80 and CD86, on antigen-presenting cells is essential for antigen-specific T cell activation. The DCs cultured from IFN-␣ refractory CML patients, in media containing IFN-␣/GM-CSF, had deficient expression of CD80 and CD86. The expression of CD86 was markedly increased when IL-4 was added to the cultures. Levels of HLA-DR also increased when three cytokines are used to prepare the DCs. Similar effects were observed in cultures of DCs from normal donors 19 and from newly diagnosed CML patients. This suggests that enhancement of DC function could potentially occur in vivo following clinical administration of IL-4 in conjunction with IFN-␣.
In order to evaluate the effects of IFN-␣ on DC differentiation in vivo, bone marrow biopsies from CML patients at diagnosis and during IFN-␣ therapy were subjected to immunohistochemical staining with antibody to fascin. In lymphohematopoietic tissues, expression of the actin-bundling protein fascin is largely restricted to DCs, with variable expression by vascular endothelial cells. 21 The DC density in bone marrow biopsies from CML patients who subsequently experienced a cytogenetic response to IFN-␣ was similar to that of normal controls, but lower than that observed in the bone marrows of patients who later failed to respond. In patients who had a cytogenetic response, a significant increase in bone marrow DC density was observed with IFN-␣ treatment compared to baseline or controls, while unresponsive patients showed no consistent change in DC density. One explanation of these results is that CML patients with abundant bone marrow DCs prior to therapy had defective DC differentiation, analogous to the impaired hematopoiesis in myelodysplastic syndrome, and the DC defect was not improved by exposure to IFN-␣. In contrast, DC differentiation was relatively normal in responsive patients and was inducible by IFN-␣, leading to accumulation of functional DCs in the bone marrow and activation of a CML-specific immune response.
In summary, these results suggest that IFN-␣ may mediate its clinical benefit in CML by inducing DC differentiation. Clinical resistance to the effects of IFN-␣ may be due to innate or acquired defects of DC differentiation in the CML clone.
